CRISPR Therapeutics
VerifiedGene-based medicines for patients with serious diseases.
Launch date
Employees
Market cap
-
Net debt
-
Enterprise valuation
$3.0b (Public information from Jul 2024)
Share price
$57.57 CRSP
Company register number CH-270.3.014.931-8
Basel Canton of Basel-Stadt (HQ)
Deals in current and previous year:
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (100 %) | 168055 % | (100 %) | 84762 % | (67 %) | 233 % | 130 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (63582 %) | 41 % | (154395 %) | (55 %) | (301 %) | (81 %) | 5 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (64248 %) | 41 % | (149123 %) | (42 %) | (374 %) | (94 %) | (19 %) |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 49161 % | 48 % | 105882 % | 105 % | - | - | - |
Source: Dealroom estimates
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor | $0.0 | round |
| investor | $0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor | $0.0 | round | |
| investor investor investor investor investor | $0.0 | round | |
| N/A | $0.0 Valuation: $0.0 | round | |
| investor | $0.0 | round | |
* | $280m | Post IPO Equity | |
| Total Funding | 000k | ||
Related Content
Recent News about CRISPR Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
